Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442970 for moderate to severe Crohn's disease
PACTR202606702924231Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing SAR442970 with Placebo (2 arms). Primary endpoint: Endoscopic response at the end of the induction period. Started Apr 2025; status: recruiting.
02
Drugs
brivekimig
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on PACTR202606702924231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606702924231.